GVD (chemotherapy)

GVD is a chemotherapy regimen, used for salvage treatment of relapsed or refractory Hodgkin disease, including those patients who relapse after stem cell transplantation.[1]

GVD regimen consists of three drugs:

(G)emcitabine
(V)inorelbine
(D)oxil - pegylated liposomal formulation of doxorubicin

Dosing

Drug	Dose in transplant-naive patients	Dose in post-transplant patients	Mode	Days
(G)emcitabine	1000 mg/m²	800 mg/m²	IV infusion	Days 1, 8
(V)inorelbine	20 mg/m²	15 mg/m²	IV bolus	Days 1, 8
(D)oxil	15 mg/m²	10 mg/m²	IV infusion	Days 1, 8

Repeated every 21 days (3 weeks).

gollark: <@711227962401226793> bees deployed.

gollark: I think it was a question booklet of some kind.

gollark: I do not.

gollark: Ojas you utterly. Yo

gollark: <@!758616423663927316> Your nickname has been changed here to enforce our naming scheme.

References

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804